Amylin announced positive results from its Phase 2 study of a once-monthly injectable suspension formulation of exenatide in patients with type 2 diabetes. This randomized, open-label study included 121 adults with type 2 diabetes who were not achieving adequate glucose control with diet and exercise alone or with a stable regimen of metformin, Actos (pioglitazone; Takeda), or both. The study assessed the efficacy of three different doses of once-monthly exenatide compared with once-weekly exenatide, which is also currently in development.
After 20 weeks of treatment (five injections), patients receiving once-monthly exenatide experienced average reductions in HbA1c ranging between 1.3 and 1.5 percentage points from baseline. In patients receiving the once-weekly exenatide injection, the reduction was 1.5 percentage points.
Exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is already available as an immediate-release subcutaneous injection (Byetta; Amylin and Lilly) for the treatment of type 2 diabetes. GLP-1 improves blood sugar after food intake through multiple effects that work in concert on the stomach, liver, pancreas and brain.
For more information call (800) 868-1190 or visit www.amylin.com.